PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
19.11%
Revenue growth under 50% of ENPH's 51.15%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
294.55%
Gross profit growth above 1.5x ENPH's 77.72%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-215.39%
Negative EBIT growth while ENPH is at 32.19%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-262.81%
Negative operating income growth while ENPH is at 32.19%. Joel Greenblatt would press for urgent turnaround measures.
-150.75%
Negative net income growth while ENPH stands at 30.25%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-149.67%
Negative EPS growth while ENPH is at 52.06%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-149.67%
Negative diluted EPS growth while ENPH is at 52.06%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.62%
Share reduction more than 1.5x ENPH's 45.36%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.62%
Diluted share reduction more than 1.5x ENPH's 45.36%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
120.36%
OCF growth above 1.5x ENPH's 2.31%. David Dodd would confirm a clear edge in underlying cash generation.
103.24%
FCF growth above 1.5x ENPH's 12.88%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
657.47%
5Y revenue/share CAGR above 1.5x ENPH's 139.32%. David Dodd would look for consistent product or market expansions fueling outperformance.
53.03%
3Y revenue/share CAGR under 50% of ENPH's 139.32%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
127.48%
Positive OCF/share growth while ENPH is negative. John Neff might see a comparative advantage in operational cash viability.
-88.02%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
No Data
No Data available this quarter, please select a different quarter.
-2819.21%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1330.25%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
72.75%
Equity/share CAGR of 72.75% while ENPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-3.62%
Negative 3Y equity/share growth while ENPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.64%
Firm’s AR is declining while ENPH shows 12.38%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
3.06%
Inventory shrinking or stable vs. ENPH's 65.76%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-5.28%
Negative asset growth while ENPH invests at 2.43%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-21.84%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
18.12%
Debt growth far above ENPH's 13.68%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-16.98%
Our R&D shrinks while ENPH invests at 4.69%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.99%
We cut SG&A while ENPH invests at 4.82%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.